Ionis Pharmaceuticals (MEX:IONS) Total Long-Term Assets: MXN9,251 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
72 GF Score
Price MXN1,150.00
GF Value MXN1,087.99
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Total Long-Term Assets?

Ionis Pharmaceuticals MEX:IONS 72 Total Long-Term Assets is MXN9,251 Mil as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 72/100 and a GF Value™ of MXN1,087.99. The stock has 6 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Ionis Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Mar. 2026 was MXN9,251 Mil.

Ionis Pharmaceuticals Total Long-Term Assets Related Terms

Ionis Pharmaceuticals Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Total Long-Term Assets Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,469.87 6,456.73 5,910.76 7,995.76 9,600.66

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,060.86 7,681.99 9,430.72 9,600.66 9,251.21
MEX:IONS
72GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of MXN9,251 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Total Long-Term Assets of MXN9,251 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Total Long-Term Assets too high?
Ionis Pharmaceuticals' current Total Long-Term Assets is MXN9,251 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Total Long-Term Assets compare to EXEL and BBIO?
Ionis Pharmaceuticals' Total Long-Term Assets of MXN9,251 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Total Long-Term Assets is MXN9,251 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Total Long-Term Assets of MXN9,251 Mil. The stock's GF Value™ is MXN1,087.99, compared to a current price of MXN1,150.00 — trading 5.7% above its estimated fair value. The current Total Long-Term Assets is MXN9,251 Mil. Ionis Pharmaceuticals' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Total Long-Term Assets is MXN9,251 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 5.7% above its estimated GF Value™ of MXN1,087.99.

Key valuation signals for MEX:IONS:

  • Total Long-Term Assets: MXN9,251 Mil
  • GF Value™: MXN1,087.99 vs. price of MXN1,150.00 (5.7% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
72GF Score

Get the complete analysis for MEX:IONS

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN1,087.99
GF Value